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6/j.bThe efficacy of donor lymphocyte infusion (DLI) for treatment of relapsed acute leukemia after allogeneic he-
matopoietic cell transplantation is limited.We hypothesized that interleukin-2 (IL-2) combined with DLI after
chemotherapy might augment graft-versus-leukemia effects. To identify a safe and effective IL-2 regimen,
a phase I/II study of DLI plus IL-2 therapy was performed for such patients. After chemotherapy, 17 patients
receivedDLI (1 108CD3/kg for patientswith related donors, and0.1 108CD3/kg for thosewith unrelated
donors) and an escalating dose of induction IL-2 (1.0, 2.0, or 3.0 106 IU/m2/day representing levels I [n5 7],
Ia [n5 9], and II [n5 1]) for 5 days followed bymaintenance (1.0 106 IU/m2/day) for 10 days as a continuous
intravenous infusion. Unacceptable IL-2–related toxicities developed in 1 patient at level I, 2 at level Ia, and 1 at
level II. Grades III-IV acute graft-versus-host disease (aGVHD) developed in 5 patients, and extensive chronic
GVHD (cGVHD) developed in 8. Eight patients had a complete remission after chemotherapy prior to DLI,
and 2 additional patients had a complete remission after DLI plus IL-2 therapy. In conclusion, the maximal tol-
erated induction dose of IL-2 combined with DLI appears to be 1.0 106 IU/m2/day. IL-2 administration after
DLI might increase the incidence of cGVHD.
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Recurrent acute leukemia after allogeneic hemato-
poietic cell transplantation (HCT) poses a challenging
clinical problem. Relapse tends to occur within 1 year
after HCT, and the prognosis is poor [1]. Although re-
mission can be induced in some patients, the median
survival for these patients is usually 6 months or less
[2]. Efficacy of a second transplantation is limited by
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bmt.2011.01.004ity, especially in adults [3,4]. Donor lymphocyte
infusion (DLI) has been used to treat recurrent
malignancy after HCT. Although the rate of
response after DLI is .70% in patients with
relapsed or persistent chronic myeloid leukemia, it is
only 15% to 29% in those with acute leukemia after
HCT [5-8]. Chemotherapy followed by DLI appears
to improve response rates and disease-free survival
(DFS) in patients with relapsed acute leukemia [9,10].
Interleukin-2 (IL-2), a 15-kDa protein secreted by
antigen-activated T cells, is critical for the generation
and maintenance of an effective immune response. IL-
2 stimulates the proliferation of antigen-specific or ac-
tivated T cells and B cells, induces expansion of natural
killer (NK) cells, induces the secretion of other
lymphokines such as interferon gamma (INF-g), gran-
ulocyte macrophage colony-stimulating factor (GM-
CSF), and tumor necrosis factor (TNF), and augments
the cytolytic function of cytotoxic T cells and NK
cells [11,12]. Moreover, lymphocytes incubated
with pharmacological concentrations of IL-2 can be-
come nonspecific cytolytic effector cells, termed
Biol Blood Marrow Transplant 17:1308-1315, 2011 1309IL-2 Combined with DLI for Relapsed Acute Leukemialymphokine-activated killer cells, which are largely
activated NK cells capable of killing fresh and cultured
tumor targets in a major histocompatibility complex
(MHC) nonrestricted fashion [13].
The failure of DLI in most patients with acute
leukemia may reflect an absent or inadequate graft-
versus-leukemia (GVL) effect. The potential effector
mechanisms of GVL, which may not be the same for
all tumors, include cytotoxic and noncytotoxic T cells,
NK cells, and secreted cytokines [14,15]. Because these
mechanisms may be enhanced by IL-2, it is postulated
that IL-2 therapy in combination with DLImight aug-
ment a GVL effect, especially after cytoreduction by
chemotherapy. The major concern, however, is that
IL-2 therapy might also increase the incidence and se-
verity of graft-versus-host disease (GVHD) associated
with DLI, because GVL and GVHDmight share sim-
ilar effector mechanisms.
Several studies explored the use of IL-2 therapy af-
ter allogeneic HCT [16-18]. The results of a phase I
study in children indicated that the maximum
tolerated dose (MTD) of IL-2 for induction was 3.0
 106/m2/day by continuous intravenous infusion for
5 days, which could be administered to prevent leuke-
mic relapse after allogeneic HCT [18]. Results from 2
encouraging reports suggested that the combination of
IL-2 with DLI was effective for treatment of diseases
refractory to DLI alone [7,19]. The feasibility and
efficacy of an escalating dose of IL-2 regimen com-
bined with a standardized dose of DLI have not yet
been determined. Here, we report the results of a pro-
spective phase I/II study of chemotherapy followed by
donor lymphocyte infusion plus IL-2 therapy for adult
patients with relapsed acute leukemia after a T cell–
replete allogeneic HCT.MATERIALS AND METHODS
Patient and Donor Eligibility
Relapse in the current study was defined by mor-
phological, flow cytometric, cytogenetic, or molecular
relapse. Patients with relapsed acute myeloid leukemia
(AML) or acute lymphoblastic leukemia (ALL) after al-
logeneic HCT were eligible for this study. Other
eligibility criteria at study registration included a
SouthwestOncologyGroup (SWOG)performance sta-
tus#2, serum creatinine concentration#2mg/dL, and
serum total bilirubin concentration #2 mg/dL. Exclu-
sion criteria included the absence of complete remission
afterHCT, the presence of preexisting congestive heart
failureor arrhythmianotmanageablewithmedical ther-
apy, pulmonary dysfunction requiring O2 therapy,
pneumonia, or severe obstruction (FEV1\50% pre-
dicted value or 50%decline frombaseline), or severe re-
strictive lung disease (total lung capacity [TLC]\60%
or50%declined frombaseline) not becauseof leukemia,and the presence of sepsis, aspergillosis, or other active
infections likely to cause death within 3months. A prior
history of DLI was not an exclusion criterion if other
study eligibility criteria were met.
The transplant donor used for DLI had to meet the
eligibility criteria for apheresis. HLA-A or B allele mis-
match was allowed for unrelated donors. Other mis-
matching was not allowed. The treatment protocol
was approved by the institutional review board (IRB)
of the FredHutchinsonCancerResearchCenter.Writ-
ten informedconsentwasobtained fromall studypartic-
ipants in accordance with the Declaration of Helsinki.Treatment Plan
Chemotherapy
Before DLI, patients received a chemotherapy reg-
imen that was appropriate for type of leukemia, prior
treatment, and response history. Patients with extra-
medullary lesions also received local irradiation, and
those with ALL or central nervous system (CNS) re-
lapse were treated with intrathecal chemotherapy.
Immunosuppressive drugs
Administration of systemic immunosuppressive
medications was withdrawn when the chemotherapy
induction regimen was started. If no flare of GVHD
was observed after 1 week from discontinuation of im-
munosuppressive medications, steroid treatment was
also tapered within 5 weeks as tolerated. Treatment
with prednisone at doses \0.5 mg/kg/day could be
continued, but the protocol required complete with-
drawal of all other systemic immunosuppressive med-
ications without GVHD exacerbation for at least 1
week before DLI. If GVHD flared, patients were
treated with high-dose prednisone (1-2 mg/kg/day),
and if the response was inadequate, other systemic im-
munosuppressive medications were added.
DLI
Patients could not have active grades II-IV acute
GVHD (aGVHD) or extensive chronic GVHD
(cGVHD) at the time of DLI. Patients were treated
with a single DLI between 27 and 180 days after che-
motherapy regardless of remission status. The cell
dose was standardized at 1.0  108 CD31 cells/kg
for patients with related donors and 0.1  108 CD31
cells/kg for those with unrelated donors.
IL-2 administration
Recombinant IL-2 (aldesleukin, Chiron, Emery-
ville, CA) was mixed in 500 mL of 5% dextrose in wa-
ter containing 0.1% human serum albumin and
administered by 24-hour continuous intravenous infu-
sion (CIV) daily for 5 days in the induction phase, us-
ing an ambulatory infusion pump starting immediately
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phase was followed by maintenance treatment with
IL-2 at 1.0  106 IU/m2/day by CIV daily for 10
days beginning on day 7. The original protocol defined
escalating dose levels of IL-2 at 1.0 (level I) and 3.0
(level II)  106 IU/m2/day for 5 days. After the unex-
pected death of the first patient treated at dose level
II, the protocol was amended to treat subsequent
patients at an intermediate induction dose of IL-2
(2.0 106 IU/m2/day; level Ia). Patients received acet-
aminophen 15 mg/kg and diphenhydramine 25 to 50
mg orally before daily doses of IL-2 during induction.
Prophylactic ciprofloxacin 500 mg orally was given
throughout the entire course of IL-2 therapy. Toxicity
during the administration of IL-2 was graded accord-
ing toWorld Health Organization criteria. Treatment
with IL-2 was discontinued when grade 3 toxicity oc-
curred in any organ or when grade 2 neurological or
cardiac toxicity occurred. If toxicity returned to base-
line or grade 1 severity within 48 hours, administration
of IL-2 was resumed at 50% of the previous dose. Any
doses missed because of toxicity were not adminis-
tered, and total duration of therapy was not extended
beyond 19 days.Statistical Considerations
The primary objective of this study was to test the
hypothesis that an IL-2 regimen similar to our previ-
ous children’s study as prophylaxis for relapse after
allogeneic HCT [18] was also tolerable when given
to adult patients who have received chemotherapy
and DLI for treatment of recurrent acute leukemia.
Study toxicity was defined as any of the following: (1)
death related to aGVHDor cGVHD, (2) development
of aGVHD or cGVHD with inability to decrease the
dose of prednisone to less than 1 mg/kg/day within 1
month after initiating treatment for GVHD, or (3)
life-threatening or fatal organ toxicity attributable to
IL-2. An excess study toxicity rate was defined as any
incidence where the lower limit of the 80% one sided
confidence interval exceeded 25%. Acute GVHD was
graded according to consensus criteria [20], and
cGVHD was classified by traditional criteria [21].
IL-2 may produce side effects of skin rash, diarrhea,
and cholestasis, which are similar clinically and patho-
logically to GVHD, but these side effects were ex-
pected to resolve soon after discontinuation of
treatment with IL-2 [18,22]. Therefore, the diagnosis
of GVHD was based on clinical characteristics such
as persistence or worsening of signs or symptoms
despite cessation of IL-2 therapy.
The secondary objective of this study was to exam-
ine the potential efficacy ofDLI plus IL-2 at the highest
acceptable dose of IL-2. However, all patients with all
dose levels were analyzed together, because the total
number of patients within each stratum was too smallfor meaningful analysis. DFS was utilized for this pur-
pose. Based on the prespecified study design, patients
were analyzed separately according to diagnosis and re-
mission status at time of DLI: patients with AML in
complete remission (CR) at the time of DLI (group 1),
and those with AML not in CR or ALL in any stage at
the time of DLI (group 2). DFS was calculated
according to the Kaplan-Meier method, beginning
from the date of DLI in patients with disease in remis-
sion at the time of DLI or from the date of remission
after DLI in patients with disease not in remission at
the time of DLI, ending at the date of relapse or death
from any cause, and censoring at the end of follow-up
for patients who survived without relapse. Patients
who never achieved complete remission were consid-
ered to have a relapse event at the date of DLI.RESULTS
Patient Characteristics
Between June 1999 and February 2005, a total of
17 patients (median age 33 years, range, 19-61) were
enrolled in this study. Patient characteristics are sum-
marized in Table 1. The underlying disease was AML
in 11 (65%) patients and ALL in 6 (35%). Two (12%)
patients had biphenotypic AML, and 3 AML cases
(18%) had emerged from myelodysplastic syndrome.
The ALL in 2 patients (12%) had a Philadelphia chro-
mosome. Sixteen patients (94%) had HCT with high-
intensity conditioning, and 1 patient (6%) had HCT
with reduced-intensity conditioning (case #17). Six
(35%) (cases #1, 2, 3, 7, 8, and 15) had extramedullary
involvement at relapse. Four (24%) received bone
marrow grafts, and 13 (76%) received growth-
factor–mobilized blood cell grafts. Donors were
HLA-identical relatives for 13 (76%) patients, HLA-
identical unrelated volunteers for 3 (18%), and an
HLA-C allele-mismatched unrelated volunteer for 1
(6%) (case #3). Two (12%) patients had received
DLI previously (cases #7 and 14). All patients received
chemotherapy before DLI plus IL-2 therapy. The me-
dian time from HCT to chemotherapy was 11.8
months (range: 3.2-121.3). The median time from
chemotherapy to DLI was 61 days (range: 36-91).
Chemotherapies for each patient are summarized in
Table 1. All patients had systemic immunosuppression
discontinued at the time of chemotherapy. The short-
est interval between discontinuation of immunosup-
pression and the first dose of IL-2 was 36 days.
Although 16 (94%) patients had a prior history of
grades II-IV aGVHD or extensive cGVHD, no pa-
tients had active GVHD at the time of DLI. Two
patients (cases #2 and 3) were receiving low-dose pred-
nisone at the time of DLI, and the remaining 15
patients were not receiving any immunosuppressive
medications at the time of DLI. At the time of DLI,
Table 1. Patient Characteristics
Study
Case #
Age at
DLI/Sex Donor
HCT
Graft
HCT to
Chemotherapy (Months)
Chemotherapy
to DLI (Days) Chemotherapy Remission at DLI
Acute myeloid leukemia
2 24 M Sib PBSC 8.4 68 HCVAD, HDAC/MTX N (Extramedullary)
3 56 M URD BM 6.4 61 Mylotarg N (Extramedullary)
5 61 F Sib BM 121.3 40 IDR + AraC Y
17 40 F Sib PBSC 16.8 53 IDR + AraC N (BM FCM <5%)
7 38 M Sib BM 63.8 50 Mylotarg N (Cytogenetic)
8 20 M Sib PBSC 5.8 75 HDAC + MIT N (Extramedullary)
10 60 F Sib PBSC 25.9 68 IDR + AraC Y
11 33 M Sib PBSC 6.0 50 IDR + AraC + ETP Y
12 22 M Sib PBSC 7.5 54 MIT + ETP Y
14 35 F Sib PBSC 17.9 77 MIT + ETP Y
15 21 F Sib PBSC 3.2 36 FLAG + IDR N (BM FCM 5%)
Acute lymphoblastic leukemia
1* 24 F Sib BM 13.4 63 HDAC + ETP N (BM FCM 0.1%)
4 34 M URD PBSC 8.7 62 HCVAD Y
16 19 F Sib PBSC 18.5 83 VCR + DNR + DEX + PEG-ASP Y
9* 21 F URD PBSC 11.9 91 VCR + DNR + PSL, FLAG N (BM FCM 0.1%)
13 29 M URD PBSC 8.4 52 VCR + AraC + MTX Y
6 50 F Sib PBSC 11.8 50 VCR + DNR + PSL + L-ASP N (Cytogenetic)
HCT indicates hematopoietic cell transplantation; Sib, sibling donor; URD, unrelated donor; PBSC, peripheral blood stem cell; BM, bone marrow;
HCVAD, fractionated cyclophosphamide + vincristine + dexamethasone + doxorubicin; HDAC, high-dose cytarabine; IDR, idarubicin; AraC, cytarabine;
FCM, flow cytometry; MIT, mitoxantrone; ETP, etoposide; FLAG, fludarabine + cytarabine + granulocyte colony-stimulating factor; DNR, daunorubicin;
PSL, prednisone; VCR, vincristine; L-ASP, L-asparaginase; DEX, dexamethasone; PEG-ASP, polyethylene glycosylated asparaginase.
*Philadelphia chromosome–positive acute lymphoblastic leukemia.
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cytogenetic, flow cytometric, or molecular evidence of
residual malignancy. Chimerism tests showed 95% to
100%donor-derivedT cells andmyeloid cells in blood
samples from all patients before DLI.
Toxicity of IL-2
All 17 patients could be evaluated for toxicity. The
toxicities of IL-2 therapy are summarized in Table 2.
Nausea, vomiting, diarrhea, body weight gain, skin
rash, and cardiovascular toxicities were frequent, but
reversible. The incidence of diarrhea and rash in-
creased in a dose-dependent fashion. Overall, grades
3-4 toxicities were observed in 1 (14%) patient at level
I, 2 (22%) at level Ia, and 1 (100%) at level II. Admin-
istration of IL-2 was discontinued in 2 (22%) patients
at level Ia because of the onset of grade III aGVHD
(case #13) and liver toxicity (case #15), respectively,
and in 1 (100%) patient at level II because of capillary
leak syndrome (case #6). One patient died with capil-
lary leak syndrome attributable to IL-2 (case #6). Pre-
specified study toxicity directly or indirectly related to
IL-2 was observed in 1 (14%) patient at level I
(GVHD), 2 (22%) at level Ia (GVHD and IL-2 re-
lated), and 1(100%) at level II (IL-2 related) (Table 3).
GVHD
All patients were evaluated for acute GVHD
(Table 3). Six of 17 (35%) patients developed grades
II-IV aGVHD after the IL-2 therapy, with a median
onset at 55 days (range: 8-74) after DLI. One of the
6 patients (case #13) developed grade III aGVHD dur-
ing IL-2 induction therapy beginning 8 days afterDLI. This patient did not receive IL-2 maintenance
therapy. The 5 patients who developed grades III-IV
aGVHD were all treated with high-dose prednisone
with or without other immunosuppressive medica-
tions such as a calcineurin inhibitor and mycopheno-
late mofetil. In 2 of the 5 patients (cases #4 and 12),
the dose of prednisone could not be decreased to\1
mg/kg/day within 1 month. The incidence rate of
grades III-IV aGVHD was significantly higher in pa-
tients with unrelated donors than in those with related
donors (3 of 4 patients versus 2 of 13 patients, P 5
.022). Absolute lymphocyte counts at and after DLI
are shown in Figure 1. Nine of 17 patients had lym-
phopenia (absolute lymphocyte count \1000/mm3)
at the time of DLI. Grades III-IV aGVHD after
DLI were more prevalent in patients with lymphope-
nia than in those with higher lymphocyte counts (5 of
9 patients versus 0 of 8 patients, P 5 .012). Fourteen
patients could be evaluated for cGVHD. Nine (64%)
of the 14 developed cGVHD, and 8 (89%) of the 9
had extensive cGVHD. The incidence rate of
cGVHD was not statistically different between pa-
tients with related donors and those with unrelated
donors (5 of 10 patients versus 3 of 4 patients, P 5
.39). We found no statistically significant difference
in the incidence of acute and cGVHD according to
the dose level of IL-2.Patient Outcome
All 8 patients in CR at DLI remained in CR after
DLI plus IL-2 therapy. Two of 9 patients (cases #3
and 15, both with AML) not in CR at DLI had a CR
after DLI plus IL-2 therapy. Overall, 10 of the 17
Table 2. IL-2 Infusion-Related Toxicity According to Dose
Level
Toxicity
IL-2 Induction Dose Level
I (n 5 7) Ia (n 5 9) II (n 5 1)
No. % No. % No. %
Nausea/vomiting
All grades 4 (57) 6 (67) 1 (100)
Grades 3-4 0 (0) 0 (0) 0 (0)
Diarrhea
All grades 2 (29) 4 (44) 0 (0)
Grades 3-4 1 (14) 1 (11) 0 (0)
Body weight gain
All grades 6 (86) 7 (78) 1 (100)
Grades 3-4 0 (0) 0 (0) 1 (100)
Kidney
All grades 2 (29) 1 (11) 1 (100)
Grades 3-4 0 (0) 0 (0) 1 (100)
Skin
All grades 2 (29) 6 (67) 1 (100)
Grades 3-4 0 (0) 1 (11) 0 (0)
Liver
All grades 1 (14) 1 (11) 1 (100)
Grades 3-4 0 (0) 1 (11) 1 (100)
Thrombocytopenia
All grades 1 (14) 1 (11) 1 (100)
Grades 3-4 0 (0) 0 (0) 1 (100)
Lung
All grades 0 (0) 0 (0) 1 (100)
Grades 3-4 0 (0) 0 (0) 1 (100)
Cardiovascular (including
hypotension)
All grades 3 (43) 3 (33) 1 (100)
Grades 3-4 0 (0) 0 (0) 1 (100)
Neurological
All grades 1 (14) 0 (0) 1 (100)
Grades 3-4 0 (0) 0 (0) 0 (0)
Overall grades 3-4 toxicities 1 (14) 2 (22) 1 (100)
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IL-2 therapy. Remission duration exceeded 1 year in
3 of 11 patients with AML (range: 12-47 months),
but all 10 patients with remission had subsequent re-
lapse. The median DFS was 8 months (range: 3-47) af-
ter DLI or the day of CR after DLI. Four patients
received a second allogeneic HCT thereafter. To
date, 1 patient (case #14) is alive at 5.4 years after che-
motherapy plus DLI plus IL-2 therapy after a second
allogeneic HCT for recurrent malignancy at 11
months after DLI plus IL-2 therapy. The other 16 pa-
tients died at a median of 11 months (range: 0.8-74)
after DLI plus IL-2 therapy. The cause of death was
leukemia except in the 1 patient who diedwith capillary
leak syndrome. As shown in Figure 2,DFS at 1 year was
40% (95% confidence interval [CI], 5.2%-75%) for
patients with AML in remission at DLI (group 1) and
8% (95% CI 0.5%-31%) for those with AML not in
CR or ALL in any stage at DLI (group 2).Figure 1. Absolute lymphocyte counts at and after DLI1IL-2 therapy.
The * indicates statistically significant differences from values before
DLI1IL-2, using a paired Mann-Whitney U-test.Protocol Amendments and Termination of the
Study
The protocol was amended twice during the study
period. First, the protocol was amended to treat subse-quent patients at an intermediate dose of IL-2 (dose
level Ia), because of an unexpected death in the first pa-
tient treated at dose level II. Second, although the tox-
icities observed with level Ia did not meet the stopping
rule according to the original protocol definition, 2 of
the 7 patients treated in this group developed clinically
significant GVHD. Based on careful review and reflec-
tion, the investigators decided to amend the protocol
to treat 20 additional patients at dose level I. The
next 2 patients (cases #14 and 15), however, received
IL-2 at dose level Ia, in violation of the protocol.
The study was closed 3 years later because of slow pa-
tient accrual.DISCUSSION
Although combination of IL-2 therapy with DLI is
a potentially effective approach for treatment of re-
lapsed leukemia after allogeneic HCT, only 2 prior
studies have reported the results of this type of treat-
ment [7,19]. Both studies reported encouraging
results after IL-2 administration in patients with recur-
rent malignancy that had not responded after DLI, but
only 4 and 2 patients in the 2 studies, respectively, had
acute leukemia. In addition, the safety and efficacy of
this treatment could not be fully evaluated because of
heterogeneity in DLI dose and schedule, the presence
or absence of prior chemotherapy, dose, and schedule
of IL-2, and the use of T cell–depleted grafts. To the
best of our knowledge, the current study is the first
prospective phase I/II clinical trial of IL-2 plus DLI
designed to treat a population that included only pa-
tients with AML or ALL that had relapsed after
T cell–replete HCT. All patients were treated with
chemotherapy followed by a single standardized dose
of DLI plus 15 days of IL-2.
In our study, IL-2 therapy was associatedwith dose-
dependent toxicities, consistent with previous reports of
studies using IL-2 in various settings [17,18,22].
Although most of the toxicities were reversible,
intolerable toxicities included severe GVHD and
severe capillary leak syndrome. Although stopping
Table 3. Outcomes after DLI plus IL-2 Therapy
Study Case # IL-2 Dose Level
GVHD after DLI
Study Toxicity* Remission after DLI
Remission Duration after
DLI (Months)Acute Chronic
Acute myeloid leukemia
2 I 0 NA N N —
3 I III Extensive N Y 33
5 I III Extensive N Y† 35
17 I 0 Extensive N N —
7 Ia 0 NA N N —
8 Ia 0 0 N N —
10 Ia II Extensive N Y† 9
11 Ia 0 Extensive N Y† 5
12 Ia IV Extensive Y (GVHD) Y† 47
14 Ia 0 0 N Y† 6
15 Ia 0 0 N Y 3
Acute lymphoblastic leukemia
1 I 0 0 N N —
4 I III Extensive Y (GVHD) Y† 8
16 I 0 0 N Y† 5
9 Ia 0 Limited N N —
13 Ia III Extensive Y (IL2) Y† 12
6 II 0 NA Y (IL-2) N —
GVHD indicates graft-versus-host disease; DLI, donor lymphocyte infusion; N, no; Y, yes; NA, not assessable.
*Death related to acute or chronic GVHD, development of acute or chronic GVHDwith inability to decrease the dose of prednisone to less than 1 mg/
kg/day within 1 month after initiating treatment for GVHD, or life-threatening or fatal organ toxicity attributable to IL-2.
†Also remission before DLI following chemotherapy.
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protocol were not met before the study was closed, we
observed study toxicities in 2 of 9 patients treated at
dose level Ia (2.0  106 IU/m2/day) and a death
associated with IL-2 administration at dose level II
(3.0 106 IU/m2/day). From these results, we conclude
that the MTD of IL-2 induction therapy by continuous
infusion after DLI appears to be dose level I (1.0  106
IU/m2/day). This MTD dose is much lower than IL-2
dose of 6-18  106 IU/day for 3 days by subcutaneous
injection combined with DLI reported by others
[7,19], but comparison is difficult because half-life of
IL-2 in plasma is as short as 2.4 hours after subcutane-
ous administration [23].Figure 2. Disease-free survival for patients with AML in complete re-
mission at DLI (group 1) and for thosewith AML not in remission or ALL
in any stage at DLI (group 2).The effects of IL-2 depend on the dose, the route
of administration, and the clinical setting. For exam-
ple, subcutaneous administration of low-dose IL-2
(0.6-1.0  106 IU/m2/day) has been found to increase
the number of CD41CD251 FOXP31 T regulatory
cells [24] and may ameliorate GVHD in the setting
of steroid-refractory cGVHD [25]. In contrast, higher
IL-2 dose regimens have been found to increase allor-
eactivity, promote GVL responses [7,19], andmay also
increase the severity of GVHD when given after DLI
by continuous infusion at doses between 1.0-3.0 
106 IU/m2/day, as observed in our study.
Our results can be interpreted in comparison with
previous studies of chemotherapy followed by DLI
without IL-2 (Table 4) [8-10]. First, the incidence
rates of grades II-IV and III-IV aGVHD in our study
are similar to those reported after DLI without IL-2.
Second, development of early grade III aGVHD (day
8 after DLI) was observed in 1 patient (case #13) in
our study, but no such cases were observed in previous
DLI studies without IL-2. Third, the 50% incidence
of extensive cGVHD in our study was somewhat
higher than the 14% to 32% incidence reported in pre-
vious studies. These findings suggest that our IL-2
regimen might induce early aGVHD and might in-
crease the incidence of cGVHD when combined
with DLI after T cell–replete HCT.
Miller et al. [26] found that lymphodepletion en-
hanced immune responses, causing severe GVHD af-
ter DLI, possibly by increasing the concentrations of
cytokines such as IL-15 and IL-7 [27]. In our study,
the risk of grades III-IV aGVHD was increased in pa-
tients who had lymphopenia at the time of DLI plus
Table 4. Summary of Previous Reports of DLI without IL-2 Followed by Chemotherapy for Relapsed Acute Leukemia and Current
Study
Parameters
Study
Collins et al. [8] Schmid et al. [10] Levine et al. [9] Current
Design Retrospective Retrospective Prospective Prospective
Disease, no. of patients
Acute myeloid leukemia 7* 124* 50* 11
Acute lymphoblastic leukemia 3* 0 0 6
DLI dose, 108/kg CD3 2.2 (mean)† 0.1 (median)‡ 1 1
Grades II-IV acute GVHD 46%† 34%‡ 45%§ 35%
Grades III-IV acute GVHD 22%† NA 28%§ 29%
Chronic GVHD 61%† 46%‡ 36%§ 64%
Chronic extensive GVHD 32%† 26%‡ 14%§ 50%
1 year DFS after DLI 54% in AML 33% in ALL NA 34% among patients in CR at DLI§ 40% in AML CR at DLI, 8.3% in others
DLI indicates donor lymphocyte infusion; GVHD, graft-versus-host disease; NA, not assessable; DFS, disease-free survival; AML, acutemyeloid leukemia;
ALL, acute lymphoblastic leukemia; CR, complete remission.
*Data abstracted from the entire cohort.
†Data represent the entire study cohort of 140 patients treated for various diagnoses, with or without chemotherapy before DLI.
‡Data represent the entire study cohort of 171 AML patients. Of the 171 patients, 124 received chemotherapy before DLI, and information was missing
in 7 patients.
§Data represent the entire study cohort of 65 patients, including 50 with AML and 15 with other diagnoses.
1314 Biol Blood Marrow Transplant 17:1308-1315, 2011Y. Inamoto et al.IL-2. Recent studies have shown that high-dose mel-
phalan, fludarabine, and cyclophosphamide all cause
lymphdepletion with increased concentrations of IL-
15 and IL-7 [28-30]. Although these specific drugs
were infrequently used in our patients, many types of
chemotherapy before DLI might have similar effects.
Durable CD81 T cell memory responses have
a strict requirement for IL-2, but recent studies high-
light a biological role of IL-2 in facilitating immune tol-
erance through generation of CD41CD251FOXP31
T regulatory cells [31]. In fact, several studies have
shown that IL-2 administration increases the number
of T regulatory cells in cancer patients [32,33] and
after CD41 DLI [24]. Therefore, IL-2 given after
DLI for treatment of recurrent acute leukemia after
HCTmaynot represent the best approach for augment-
ing GVL effects associated with DLI in the future.
Other gc-signaling cytokines such as IL-7, IL-9, IL-
15, and IL-21 may offer alternative choices for aug-
menting GVL, because most of these cytokines have
positive effects on the maintenance of CD81T cell sur-
vival and function in vivo but do not affect growth of
T regulatory cells [34-36].
This study was closed because of slow patient ac-
crual, and the small sample size limits the ability to
draw definitive conclusions regarding the efficacy of
DLI plus IL-2. Nonetheless, the 1-year DFS rates of
40% among patients with AML in remission at DLI
werenot inferior to the 34%to54%DFSrates after che-
motherapy followed by DLI without IL-2 in previous
studies (Table 4) [8]. The remission duration exceeding
1 year in 3 patients treated for recurrent AMLwas nota-
ble.These results support the previous finding byNadal
et al. [19] that DLI plus IL-2 treatment was more effec-
tive for patientswithAML than for those with other dis-
eases. Previous studies using continuous intravenousIL-2 at doses as low as 0.2-0.6 IU/m2/day after alloge-
neicHCTshowed that IL-2promoted expansion ofNK
cells but did not increase the numbers of CD31 T cells
[17,37]. Recent studies have shown that mismatches of
killer immunoglobulin-like receptors (KIR) were
associated with reduced rates of leukemia relapse
through alloreactive NK cells, particularly for patients
with AML [15,38]. By augmenting NK alloreactivity,
IL-2 may augment GVL effects, particularly in patients
with AML. In conclusion, MTD of continuous intrave-
nous IL-2 induction therapy combined with DLI ap-
pears to be 1.0  106 IU/m2/day. IL-2 after DLI
might increase the incidence of cGVHD, although
the antileukemia efficacy of this treatment remains to
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